JM KIRKWOOD, MS ERNSTOFF, CA DAVIS, … - Annals of internal medicine, 1985 - Am Coll Physicians In two phase I-II trials, 33 patients were given recombinant interferon alpha-2
daily at dosages of 3, 10, 30, 50, or 100 MU/d for up to 4 weeks by
intramuscular or intravenous routes. Dose-limiting toxicities, including ... Cited by 99 - Related articles - All 4 versions
A COATES, M RALLINGS, P HERSEY, C … - Journal of interferon research, 1986 - liebertonline.com Page 1. JOURNAL OF INTERFERON RESEARCH 6:01-04 (1986) Mary Ann Lieber!, Inc.,
Publishers Phase-II Study of Recombinant ce2-Interferon ... Cited by 42 - Related articles - All 3 versions
A Steiner, C Wolf, H Pehamberger - Journal of cancer research and clinical oncology, 1987 - Springer Page 1. J Cancer Res Clin Oncol (1987) J t 3:459-465 C~i~icer esearch
,~linical 9 9 Springer-Verlag 1987 Comparison of the effects ... Cited by 31 - Related articles - All 4 versions
ET Creagan, DL Ahmann, SJ Green, HJ Long, … - CA A Cancer Journal for Clinicians - interscience.wiley.com Thirty-one patients with disseminated malignant melanoma received intramuscular
recombinant leukocyte A interferon (rIFN- A), 50 × 10 6 units/m 2 three times
weekly for a planned treatment duration of 3 months. Seven objective ... Cited by 94 - Related articles - All 3 versions
- ►nih.gov [PDF] P Hersey, E Hasic, M MacDonald, A Edwards, … - British Journal of Cancer, 1985 - pubmedcentral.nih.gov Summary Studies were initiated to assess the response of patients with
disseminated melanoma to recombinant a interferon (rIFN-aA) and to monitor
effects of rIFN-aA on several tests of immune function. Twenty patients ... Cited by 49 - Related articles - All 4 versions
T Dorval, T Palangie, M Jouve, E Garcia-Giralt, … - CA A Cancer Journal for Clinicians - interscience.wiley.com Twenty-four patients with historically proven metastatic malignant melanoma were
included in a Phase II trial of human DNA recombinant interferon (rDNA IFN 2).
They were given 10 × 10 6 IU of IFN 2 subcutaneously three times a week ... Cited by 40 - Related articles - All 3 versions
ET Creagan, DL Ahmann, S Frytak, HJ Long, … - CA A Cancer Journal for Clinicians - interscience.wiley.com In three consecutive Phase II trials of recombinant interferon alfa-2a (rIFN
alfa-2a; Roferon®-A Hoffmann-La Roche, Nutley, NJ) involving 96 patients with
advanced malignant melanoma, an overall response rate of 22% was observed. ... Cited by 47 - Related articles - All 2 versions
SS Legha, NEJ Papadopoulos, C Plager, S … - Journal of Clinical Oncology, 1987 - jco.ascopubs.org In the article by Legha et al entitled "Clinical Evaluation of Recombinant
Interferon Alfa-2A (Roferon-A) in Metastatic Melanoma Using Two Different
Schedules," which appeared in the August 1987 issue (Vol 5, pp ... Cited by 40 - Related articles - All 5 versions
- ►ascopubs.org [PDF] ET Creagan, DL Ahmann, SJ Green, HJ Long, S … - Journal of Clinical Oncology, 1984 - jco.ascopubs.org From the Division of Medical Oncology and Cancer Center Statistics, Mayo Clinic,
Rochester, Minn; and Hoffmann- LaRoche Inc, Nutley, NJ. Submitted Feb 6, 1984;
accepted May 22, 1984. Address requests for reprints to Edward T. Creagan, ... Cited by 46 - Related articles - All 5 versions
SE Krown, MW Burk, JM Kirkwood, D Kerr, DL … - Cancer treatment reports, 1984 - ncbi.nlm.nih.gov Forty-four evaluable patients with metastatic malignant melanoma confined to the
skin, subcutaneous tissues, lymph nodes, and/or lung were randomly assigned to
receive either 1 X 10(6), 3 X 10(6), or 9 X 10(6) units of partially ... Cited by 52 - Related articles - All 2 versions
